Kari Bailey, MD, on the changing landscape for advanced therapies in OAB

In this interview, Kari Bailey, MD, recaps the session, “Making Sense of Advanced Technologies to Integrate into your OAB Program,” which was presented at the 2024 LUGPA Annual Meeting in Chicago, Illinois. Bailey is a urologist and the head of the women’s health department at AAUrology in Annapolis, Maryland.

Video Transcript:

Could you recap the LUGPA session, “Making Sense of Advanced Technologies to Integrate into your OAB Program”?

Our main point in that session was that advanced therapies are being underutilized in overactive bladder. The guidelines have changed. They used to be called third-line therapies, and they're no longer quote "third-line" anymore, based on the new guidelines that have come out. Because of this, you don't have to try and fail bunches of medications; you can start with them sooner than previous, but a lot of people aren't using them. There are longer lasting therapies. There's a lot of advancements in them. Our main takeaway was this is what's new, use them, because we're underutilizing them.

Could you expand on the recent advancements in OAB?

With advanced therapies in overactive bladder, focusing on nerve modulation, there's been a big advancements in the technology, the battery life, ability to recharge, which gives patients a longer lasting therapy. There's also been new advancements in implantable tibial nerve stimulation, and that field is going to be continuing to expand and giving patients more access to minimally invasive therapies for overreactive bladder.

This transcript was AI generated and edited by human editors for clarity.